Breast (Jun 2021)

Long-term patient reported outcomes and hematologic toxicity among patients who received Granulocyte-Colony Stimulating Factors during chemotherapy for early breast cancer

  • Pietro Lapidari,
  • Arnauld Gbenou,
  • Julie Havas,
  • Elise Martin,
  • Barbara Pistilli,
  • Anne-Laure Martin,
  • Sibille Everhard,
  • Charles Coutant,
  • Paul Cottu,
  • Anne Lesur,
  • Florence Lerebours,
  • Olivier Tredan,
  • Laurence Vanlemmens,
  • Christelle Jouannaud,
  • Christelle Levy,
  • Olivier Rigal,
  • Marion Fournier,
  • Fabrice Andre,
  • Ines Vaz-Luis,
  • Antonio Di Meglio

Journal volume & issue
Vol. 57
pp. 43 – 48

Abstract

Read online

We assessed long-term associations of Granulocyte-Colony Stimulating Factors (G-CSF) use with patient-reported outcomes (PROs) and hematologic toxicity among chemotherapy-treated, early-stage breast cancer patients in CANTO (NCT01993498).Among 2920 patients longitudinally followed-up until year-4 after diagnosis, 49% used G-CSF. In multivariable-adjusted mixed-models, EORTC QLQ-C30 pain and summary score were not substantially different between groups (overall adjusted mean difference, use vs no-use [95%CI]: +1.27 [-0.33 to +2.87] and −1.01 [-1.98 to −0.04], respectively). PROs were slightly worse at year-4 among patients receiving G-CSF, although differences were of trivial clinical significance. No major differences were observed in leukocyte or platelet count over time.

Keywords